Qiagen, Lilly eye panel to ID patients at risk for developing Alzheimer’s

 

QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with Alzheimer’s Disease // Collaboration set to launch the first commercially available IVD Kit for APOE genotyping

https://www.globenewswire.com/news-release/2024/09/04/2940895/8690/en/QIAGEN-and-Lilly-collaborate-to-support-development-of-a-QIAstat-Dx-IVD-panel-that-identifies-patients-at-risk-for-developing-Alzheimer-s-disease.html